Biogen up on new drug news

Investor's Business Daily

The biotech released positive trial data on its late-stage hemophilia candidate. Biogen (BIIB) also got more positive analyst comments regarding its Wed. deal to buy out Elan's (ELN) stake in the blockbuster Tysabri multiple sclerosis drug. Shares rose 2.6% to 164.44.

View Comments (0)